5Y Capital

Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.

Medvance is a pioneer in the development of 3D printed medical implants, specifically using PEEK materials. The company specializes in creating medical 3D printing equipment and software tailored for advanced medical engineering. By providing innovative 3D printing solutions, Medvance aims to enhance medical outcomes for patients and healthcare professionals. Its strategic partnership with Evonik ensures a reliable supply of raw materials, further supporting Medvance's mission to deliver cutting-edge medical technologies. The company's initiatives are focused on improving healthcare in China and expanding its impact globally.

Triastek Co. Ltd., founded in 2015 and based in Nanjing, China, specializes in the manufacture of 3D printed pharmaceuticals and related medical equipment. The company offers a range of products, including blockbuster and orphan drugs, as well as complex drug delivery technologies. Triastek develops proprietary 3D printing technology that encompasses the entire process from drug formulation design to continuous production. Its Melt Extrusion Deposition (MED) technology is applicable to solid formulations, enabling innovative drug delivery and development solutions. The company has also filed patent applications for its technologies, emphasizing its commitment to advancing pharmaceutical manufacturing through 3D printing.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

IrisVR, Inc. is a company that specializes in developing virtual reality software applications tailored for the architecture, engineering, and construction industries. Founded in 2014 and based in New York, IrisVR offers two primary products: Prospect and Scope. Prospect is a desktop application that converts 3D models into immersive VR experiences, compatible with devices such as HTC Vive and Oculus Rift. Scope, on the other hand, is a mobile solution designed for viewing 360° panoramas and allows users to interact with VR content using devices like Samsung GearVR and Google Daydream. The software integrates seamlessly with popular 3D modeling tools, enabling design and construction teams to collaborate effectively and make informed decisions by visualizing projects in a realistic, immersive environment. By providing these innovative solutions, IrisVR enhances the design review process and supports the implementation of complex construction workflows.

IrisVR, Inc. is a company that specializes in developing virtual reality software applications tailored for the architecture, engineering, and construction industries. Founded in 2014 and based in New York, IrisVR offers two primary products: Prospect and Scope. Prospect is a desktop application that converts 3D models into immersive VR experiences, compatible with devices such as HTC Vive and Oculus Rift. Scope, on the other hand, is a mobile solution designed for viewing 360° panoramas and allows users to interact with VR content using devices like Samsung GearVR and Google Daydream. The software integrates seamlessly with popular 3D modeling tools, enabling design and construction teams to collaborate effectively and make informed decisions by visualizing projects in a realistic, immersive environment. By providing these innovative solutions, IrisVR enhances the design review process and supports the implementation of complex construction workflows.

Virtroid is a technology company that specializes in creating a three-dimensional (3D) application designed to assist individuals in producing photorealistic 3D content. The application leverages virtual reality and augmented reality to enhance the real estate search and interior design experience. By enabling users to visualize furniture, flooring, and other products in their own homes in real time, Virtroid offers a convenient and engaging way to explore design possibilities. This innovative approach aims to make the process of selecting and arranging home decor more accessible and enjoyable for clients.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.